Related Experiment Videos
Lethal arthrogryposis multiplex congenita: a pathological study of 21 cases
C M Quinn1, J S Wigglesworth, J Heckmatt
1Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Histopathology
|August 1, 1991
Summary
This study investigated lethal arthrogryposis multiplex congenita cases, finding myogenic and neurogenic origins are key. Muscle histochemistry and neuropathology are vital for assessing recurrence risks in these complex conditions.
Area of Science:
- Pediatric Pathology
- Neuromuscular Disorders
- Medical Genetics
Background:
- Arthrogryposis multiplex congenita (AMC) encompasses a group of non-progressive neuromuscular disorders.
- Lethal forms of AMC often present diagnostic challenges, necessitating detailed etiological investigation.
- Prenatal diagnosis and termination of affected pregnancies highlight the need for accurate recurrence risk assessment.
Purpose of the Study:
- To determine the underlying causes of lethal AMC cases.
- To evaluate the utility of histochemical and histological muscle analysis in diagnosing AMC subtypes.
- To identify factors influencing familial recurrence in lethal AMC.
Main Methods:
- Histochemical and histological examination of muscle tissue from 21 deceased AMC cases.
- Neuropathological assessment for neurogenic causes.
- Syndrome recognition techniques were employed but found limited.
Main Results:
- Myogenic origin identified in 11 cases (10 congenital muscular dystrophy, 1 nemaline rod myopathy).
- Neurogenic origin confirmed in 5 cases (intra-uterine anoxic-ischaemic damage, cerebro-ocular-facio-skeletal syndrome).
- Causation remained uncertain in 5 cases; diaphragmatic and lung hypoplasia were common, as was birth trauma.
Conclusions:
- Muscle histochemistry and neuropathology are essential for accurate diagnosis and etiological determination in lethal AMC.
- Myogenic causes were associated with higher familial recurrence rates.
- Accurate etiological diagnosis is crucial for predicting recurrence risks in lethal AMC, surpassing syndrome recognition alone.